{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 67 of 129', '10.3.1.3 Scoring Atopic Dermatitis', 'The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with', 'subjective symptoms (28). Details on the scoring of extent and severity of AD according to', 'SCORAD are included in the efficacy assessment & C-SSRS manual. The maximum total', 'score is 103, with higher values indicating more severe disease. SCORAD will be assessed', 'according to the schedule of procedures (Section 4).', 'The assessment will be based on the condition of the disease at the time of evaluation and not', 'in relation to the condition at a previous visit. Whenever possible, SCORAD should be', 'assessed by the same investigator at each visit to reduce inter-rater variability.', 'The assessment consists of 3 components: A = extent, B = intensity, and C = subjective', 'symptoms.', 'Extent (A)', 'The extent of AD is assessed as a percentage of each defined body area and reported as the', 'sum of all areas (maximum score = 100%)', 'Intensity (B)', 'The intensity of 6 specific symptoms of AD (erythema, oedema/papulation, oozing/crusting,', 'excoriation, lichenification, and dryness) is assessed by the investigator on an average', 'representative area using the following scale:', '0', '=', 'None/absent', '1', '=', 'Mild', '2', '=', 'Moderate', '3', '=', 'Severe', 'Note: dryness is evaluated on uninvolved areas.', 'The sum of intensity score of the 6 symptoms will be reported (maximum score = 18).', 'Subjective symptoms (C)', 'A subjective assessment of the average itch and sleeplessness over the last 3 days/nights is', 'recorded for each symptom by the subject on a visual analogue scale, where 0 is no itch (or', 'sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum', 'possible score of 20.', 'The SCORAD is calculated as: A/5+7B/2+C', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 68 of 129', '10.3.1.4 Atopic dermatitis flares', 'An AD flare is defined as an acute, clinically significant worsening of signs and symptoms of', 'AD requiring therapeutic intervention (29). For the purpose of this protocol, AD flares are', 'defined as worsening of the disease that requires escalation/intensification of AD treatment', 'reported after initiation of IMP; this will also include initiation or intensification of the TCS', '(NIMP) supplied to the subjects. Flares will be assessed at the clinic according to the schedule', 'of procedures (see Section 4). Subjects who experience disease worsening between scheduled', 'trial visits should return to the clinic for an unscheduled visit for assessment of flare before', 'initiating the treatment escalation; subjects who return to the clinic for assessment of flares at', 'an unscheduled visit should undergo IGA and EASI assessments, and information on', 'concomitant medications/procedures and AEs should be collected.', 'Details on rescue treatments and prohibited concomitant medications and procedures for', 'treatment of AD are provided in Sections 9.6 and 9.5.', '10.3.2 Subject assessments', 'Six PROs will be assessed daily using an eDiary:', 'Eczema-related Sleep NRS (Section 10.3.2.1).', 'Worst Daily Pruritus NRS (Section 10.3.2.2).', 'Average Daily Pruritus NRS (Section 10.3.2.3).', 'Patient Days of Topical Treatment Use (Section 10.3.2.4).', 'Patient Global Impression of Bother (PGI-B) (Section 10.3.2.5.', 'Patient Global Impression of Severity (PGI-S) (Section 10.3.2.6).', 'Subjects will receive eDiary training at the screening visit 14 days before baseline (Week -2;', 'visit 2) and start the eDiary.', 'In addition, 4 PROs will be completed by the subjects at the site:', 'Patient Oriented Eczema Measure (POEM) (Section 10.3.2.7).', 'Dermatology Life Quality Index (DLQI) (Section 10.3.2.8).', 'EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L)', '(Section 10.3.2.9).', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}